MiR-18a increases PD-L1 levels by targeting SOX6 (p53 pathway activator) to inhibit p53 signaling in cervical cancer (104), and nutlin-3a, a small molecule activator of wild-type p53, enhances the expression of PD-L1 in breast cancer (320). Here, CD274 is linked to cervical cancer.